English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Before the recent approvement of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration (AMD), bevazicumab (Avastin) had been successfully used as an off-label treatment for this condition.1 As a consequence, in daily practice we are confronted with a large number of patients having received Avastin injections in the past, now facing a recurrence of the disease and therefore requiring additional injections.2 This leaves the ophthalmologist in a medical dilemma: should one continue with the off-label drug Avastin or switch to Lucentis? From a clinical point of view and disregarding the legal aspects of continuing …

How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis?